Details for Patent: 5,260,291

Summary for Patent: 5,260,291

Title:	Tetrazine derivatives
Abstract:	[ 3H]-Imidazo[ 5,1-d] -1,2,3,5-tetrazin-4-one derivatives of the formula: ##STR1## wherein R.sup.1 represents hydrogen, or an alkyl, alkenyl or alkynyl group containing up to 6 carbon atoms, each such group being unsubstituted or substituted by from one to three substituents selected from halogen atoms, alkoxy, alkylthio, alkylsulphinyl and alkylsulphonyl groups containing up to 4 carbon atoms, and optionally substituted phenyl groups, or R.sup.1 represents a cycloalkyl group containing from 3 to 8 carbon atoms, and R.sup.2 represents a carbamoyl group optionally N-substituted by one or two groups selected ftom alkyl and alkenyl groups containing up to 4 carbon atoms, and cycloalkyl groups containing 3 to 8 carbon atoms, are new therapeutically useful compounds possessing antineoplastic and immunomodulatory activity.
Inventor(s):	Lunt; Edward (Norfolk, GB2), Stevens; Malcolm F. G. (Birmingham, GB2), Stone; Robert (Montrose, AU), Wooldridge; Kenneth R. H. (Lincolnshire, GB2), Newlands; Edward S. (London, GB2)
Assignee:	Cancer Research Campaign Technology Limited (London, GB2)
Application Number:	07/781,020
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 5,260,291

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 5,260,291

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	8125791	Aug 24, 1981

International Family Members for US Patent 5,260,291

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	380256
Austria	A319182
Australia	571430
Australia	5838494
Australia	6371198
Australia	8749382
Belgium	894175